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M
easurement of peripheral 
blood CD4 T lymphocytes is 
probably the most important 
laboratory assay for evaluation and 
monitoring of patients with HIV. The 
CD4 count is critical for determining 
the clinical stage of HIV infection, for 
deciding when to start antiretroviral 
therapy (ART), for evaluating the 
efﬁ  cacy of treatment, and for changing 
the medications when necessary. Most 
HIV treatment decisions are therefore 
based upon the CD4 count [1–3]. 
Flow Cytometry
The most common technique for 
measuring CD4 counts in developed 
country settings is ﬂ  ow cytometry. 
Flow cytometers use lasers to excite 
ﬂ  uorescent antibody probes speciﬁ  c 
for various cell surface markers, such as 
CD3, CD4, and CD8, which distinguish 
one type of lymphocyte from another. 
As Rodriguez et al. point out in their 
study in this issue of PLoS Medicine [4], 
the cost of a ﬂ  ow cytometer ranges 
from $30,000 to $150,000, and the 
reagents needed for determining the 
lymphocyte surface markers by this 
method are very costly. In addition, use 
of ﬂ  ow cytometry requires technical 
and operational expertise as well as a 
reliable electricity source. Considering 
all these factors together, it is no 
surprise that CD4 measurements 
cannot be widely applied in developing 
world settings. 
Why CD4 Counts Matter 
in Developing Countries
This grim reality—the lack of facilities 
to measure CD4 counts in poor 
countries—stands in sharp contrast 
to the urgent need for instituting 
rational and effective ART in these 
countries. The absence of tools to 
measure CD4 counts clearly jeopardizes 
the success of the recently launched 
global campaigns to ﬁ  ght AIDS, 
such as those of the World Health 
Organization and the Global Fund to 
Fight AIDS, Tuberculosis, and Malaria. 
These campaigns aim to distribute 
ART to millions of people with HIV, 
mostly living in developing countries. 
Regretfully, it is highly likely that these 
major efforts will fail, unless improved 
and widely used means for counting 
CD4 cells become available and can be 
applied where they are most needed. 
Since at least 35 million people are 
infected with HIV, and several million 
of them are in need of urgent lifesaving 
ART, the issue of CD4 monitoring has 
become a crucial one. 
Rodriguez et al. point out that 
several efforts have been made to 
develop alternative, affordable CD4 
counting methods for resource-poor 
settings [4]. These include improved 
ﬂ  ow cytometric approaches and 
microbead capture/separation of CD4 
cells followed by manual cell counting 
[5–8]. Also, new single-purpose ﬂ  ow 
cytometers have been designed that 
perform the test at a much lower price. 
Though all these assays are indeed 
cheaper than regular ﬂ  ow cytometry, 
they suffer from decreased accuracy 
and, most importantly, they are all of 
low throughput. 
A New Method for Counting CD4
Rodriguez et al. describe a novel 
method for counting CD4 in 
resource-poor settings (Figure 1) 
[4]. The method is based on a novel 
microchip detection system for 
measuring various analytes in very 
small volumes. A series of chemical 
and immunological reactions carried 
out on microspheres are visualized 
and captured on a charge-coupled 
device (developed for digital camera 
technology). This method allows for 
accurate measurement of CD4, CD8, 
and CD4/CD8. The prototype used for 
demonstration of the new apparatus 
shows extremely good agreement with 
currently used ﬂ  ow cytometry. Most 
importantly, the investigators claim that 
the cost of each assay is much lower 
than that for ﬂ  ow cytometry. 
There are, however, a number of 
unresolved issues in this study that 
need further clariﬁ  cation before 
the assay can meet the expectations 
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Figure 1. CD4 Cell Measurement Using a 
Prototype Microchip Counting Method 
This is a digital image of whole blood from a 
ﬁ  ve-month-old male infant from Botswana 
with an absolute CD4 count of 2,098 cells/
ml and a CD4 percentage of T cells of 0.39, 
obtained using a prototype method for 
low-cost CD4 count monitoring. CD4+ T cells 
are yellow. Also visualized are monocytes 
(green) and CD8+ T cells (red). (Photo 
courtesy of the authors of [8].)PLoS Medicine  |  www.plosmedicine.org 0596
for becoming a widely used tool in 
resource-poor settings. Firstly, the 
study was performed with a prototype 
apparatus, tailored to meet the 
requirements of the study, but not 
yet representing a commercially 
established and viable production line. 
Secondly, though the authors state that 
the price of each CD4 determination 
will become much cheaper, it is not 
clear how much each assay will cost in 
the end, and whether the ﬁ  nal cost is 
realistic in the context of developing 
countries. It is clear, though, that the 
actual price of the assay will change 
once it is widely and consistently used 
on a large scale. Thirdly, although a 
few children were tested (six infants in 
total), the results in this small group 
remain questionable, and therefore 
the application of the test to pediatric 
populations needs further testing. 
It may well be that application to 
pediatric patients will require an 
improved apparatus or improved 
handling. 
Conclusion
Despite these reservations, the authors 
of this study should be commended for 
addressing an extremely important issue 
and developing this novel approach 
for counting CD4 in patients with 
HIV. Their study may lead to further 
development of such an apparatus, 
which is sorely needed for the global 
ﬁ  ght against AIDS. Such efforts will 
hopefully be noticed by public funding 
agencies, leading to the improvement of 
tools for measuring CD4 counts.  
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